Outcome of intracerebral hemorrhage associated with different oral anticoagulants

TLDR

The study compared 90‑day mortality, functional outcome, ICH volume, and hematoma expansion between intracerebral hemorrhage related to non‑vitamin K antagonist oral anticoagulants and that related to vitamin K antagonists. Using an international multicenter pooled cohort of 500 patients, the authors performed adjusted Cox proportional hazards and logistic regression analyses, accounting for age, sex, baseline GCS, ICH location, volume, intraventricular hemorrhage, surgery, and heterogeneity via a shared frailty term, with volume measured by ABC/2 or planimetry and hematoma expansion defined as >33 % or >6 mL increase within 72 h. The analysis found no significant differences between NOAC‑ICH and VKA‑ICH in 90‑day mortality (33 % vs 31 %), hematoma expansion (40 % vs 34 %), or functional outcome at discharge, and baseline ICH volumes were comparable.

Abstract

<h3>Objective:</h3> In an international collaborative multicenter pooled analysis, we compared mortality, functional outcome, intracerebral hemorrhage (ICH) volume, and hematoma expansion (HE) between non–vitamin K antagonist oral anticoagulation–related ICH (NOAC-ICH) and vitamin K antagonist–associated ICH (VKA-ICH). <h3>Methods:</h3> We compared all-cause mortality within 90 days for NOAC-ICH and VKA-ICH using a Cox proportional hazards model adjusted for age; sex; baseline Glasgow Coma Scale score, ICH location, and log volume; intraventricular hemorrhage volume; and intracranial surgery. We addressed heterogeneity using a shared frailty term. Good functional outcome was defined as discharge modified Rankin Scale score ≤2 and investigated in multivariable logistic regression. ICH volume was measured by ABC/2 or a semiautomated planimetric method. HE was defined as an ICH volume increase &gt;33% or &gt;6 mL from baseline within 72 hours. <h3>Results:</h3> We included 500 patients (97 NOAC-ICH and 403 VKA-ICH). Median baseline ICH volume was 14.4 mL (interquartile range [IQR] 3.6–38.4) for NOAC-ICH vs 10.6 mL (IQR 4.0–27.9) for VKA-ICH (<i>p</i> = 0.78). We did not find any difference between NOAC-ICH and VKA-ICH for all-cause mortality within 90 days (33% for NOAC-ICH vs 31% for VKA-ICH [<i>p</i> = 0.64]; adjusted Cox hazard ratio (for NOAC-ICH vs VKA-ICH) 0.93 [95% confidence interval (CI) 0.52–1.64] [<i>p</i> = 0.79]), the rate of HE (NOAC-ICH n = 29/48 [40%] vs VKA-ICH n = 93/140 [34%] [<i>p</i> = 0.45]), or functional outcome at hospital discharge (NOAC-ICH vs VKA-ICH odds ratio 0.47; 95% CI 0.18–1.19 [<i>p</i> = 0.11]). <h3>Conclusions:</h3> In our international collaborative multicenter pooled analysis, baseline ICH volume, hematoma expansion, 90-day mortality, and functional outcome were similar following NOAC-ICH and VKA-ICH.